About Avilar
Avilar is a company based in Waltham (United States) founded in 2020 by James Kasuboski and Milind Deshpande. Avilar has raised $75.28 million across 1 funding round from investors including RA Capital, Sanofi Ventures and Medical Excellence Capital. The company has 12 employees as of December 31, 2022. Avilar offers products and services including ATAC Platform and MTAC Platform. Avilar operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Waltham, United States
- Employees 12 as on 31 Dec, 2022
- Founders James Kasuboski, Milind Deshpande
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Avilar Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$75.28 M (USD)
in 1 rounds
-
Latest Funding Round
$75.28 M (USD), Seed
Dec 14, 2020
-
Investors
RA Capital
& 3 more
-
Employee Count
12
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Avilar
Avilar offers a comprehensive portfolio of products and services, including ATAC Platform and MTAC Platform.
Harnesses ASGPR for degrading extracellular proteins in drug development.
Enables degradation of proteins using endogenous machinery for therapeutics.
People of Avilar
Unlock access to complete
Unlock access to complete
Leadership Team
11 people
Product Management Team
2 people
Head Team
1 people
Co Team
1 people
Scientist Team
1 people
Unlock access to complete
Funding Insights of Avilar
Avilar has successfully raised a total of $75.28M through 1 strategic funding round. The most recent funding activity was a Seed round of $75.28 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Avilar
Avilar has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, Sanofi Ventures and Medical Excellence Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Locked | Locked | Locked | |
|
Capital is invested in early-stage life sciences ventures.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Avilar
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avilar
Investment portfolio details for Avilar
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Avilar
Detailed financials for Avilar
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Avilar Comparisons
Peer comparison for Avilar
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Avilar
Avilar operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Avilar
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Avilar
Complete news archive for Avilar
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avilar
Avilar was founded in 2020.
Avilar is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Daniel Grau is the current CEO of Avilar.
Avilar is a funded company, having raised a total of $75.28M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at Avilar is 12.
Avilar was founded in 2020 and is based in Waltham, United States. A proprietary platform has been established in the biotech sector for developing extracellular protein degraders called ATACs. Disease-causing proteins are shuttled by these degraders from circulation to the endolysosome for breakdown. Broad applications are targeted across various diseases through this drug discovery approach.
Avilar's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Avilar offers ATAC Platform and MTAC Platform.
Avilar has 4 investors. Key investors include RA Capital, Sanofi Ventures, Medical Excellence Capital, and Astellas Venture Management.